Serum L-ficolin levels in patients with systemic lupus erythematosus

Mod Rheumatol. 2012 Nov;22(6):899-902. doi: 10.1007/s10165-012-0616-y. Epub 2012 Feb 21.

Abstract

Objective: L-ficolin plays an important role in innate immunity and is involved in apoptosis. The objective of this study was to investigate the relationship between serum L-ficolin levels and clinical manifestations in patients with systemic lupus erythematosus (SLE).

Methods: Serum L-ficolin levels were determined by enzyme-linked immunosorbent assay in 66 SLE patients and 50 healthy controls.

Results: Median serum L-ficolin levels were 5.0 and 8.7 μg/ml in SLE patients and controls, respectively (p = 0.0001). There were no significant differences in serum L-ficolin levels between the active disease group [SLE Disease Activity Index (SLEDAI) >6] and the inactive disease group (SLEDAI <5). Decreased serum L-ficolin levels were associated with thrombocytopenia (median of with vs. without thrombocytopenia 3.4 vs. 5.3 μg/ml, p = 0.008). There were no correlations between serum L-ficolin levels and SLEDAI, serum C3, or serum C4 levels.

Conclusion: The association between L-ficolin and thrombocytopenia suggests a pathogenic role for L-ficolin in thrombocytopenia in SLE.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Female
  • Humans
  • Lectins / blood*
  • Lupus Erythematosus, Systemic / blood*
  • Lupus Erythematosus, Systemic / complications
  • Male
  • Middle Aged
  • Severity of Illness Index
  • Thrombocytopenia / blood*
  • Thrombocytopenia / complications

Substances

  • Lectins
  • ficolin